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Summary
Objectives—Carisbamate (CRS) is a novel monocarbamate compound that possesses anti-
seizure and neuroprotective properties. However, the mechanisms underlying these actions remain 
unclear. Here, we tested both direct and indirect effects of CRS on several cellular systems that 
regulate intracellular calcium [Ca2+]i.
Methods—We used a combination of cellular electrophysiological techniques, as well as cell 
viability, Store Overload-Induced Calcium Release (SOICR), and mitochondrial functional assays 
to determine whether CRS might affect release Ca2+ levels through actions on the endoplasmic 
reticulum (ER), mitochondria, and/or T-type voltage-gated Ca2+ channels.
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Results—In CA3 pyramidal neurons, kainic acid induced significant elevations in [Ca2+]i and 
long-lasting neuronal hyperexcitability, both of which were reversed in a dose-dependent manner 
by CRS. Similarly, CRS suppressed spontaneous rhythmic epileptiform activity in hippocampal 
slices exposed to zero-Mg2+ or 4-AP. Treatment with CRS also protected murine hippocampal 
HT-22 cells against excitotoxic injury with glutamate, and this was accompanied by a reduction in 
[Ca2+]i levels. Neither KA nor CRS alone altered the mitochondrial membrane potential (ΔΨ) in 
intact, acutely isolated mitochondria. Additionally, CRS did not affect mitochondrial respiratory 
chain activity, Ca2+-induced mitochondrial permeability transition and Ca2+ release from the ER. 
However, CRS significantly decreased Ca2+ flux in HEK tsA-201 cells transfected with Cav3.1 
(voltage-dependent T-type Ca2+) channels.
Significance—Our data indicate that the neuroprotective and anti-seizure activity of CRS likely 
results in part from decreased [Ca2+]i accumulation through blockade of T-type Ca2+ channels.
Keywords
carisbamate; mechanism; calcium; T-type calcium channel; neuroprotection; kainic acid; 
mitochondria; endoplasmic reticulum; ryanodine receptor
Introduction
Carisbamate (CRS; RWJ333369, (S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol) is an 
investigational compound that has shown broad-spectrum efficacy against seizures in animal 
models and appears to exert neuroprotective effects.1 Clinically, CRS has been shown to be 
effective and well tolerated in patients with refractory focal-onset seizures.2,3 However, 
larger phase III clinical trial failed to document significant seizure reduction over the dose 
range studied.4 Notwithstanding these results, CRS has recently been shown to enhance 
behavior and cognition in a model of TLE,5 suggesting possible usefulness in controlling co-
morbid symptoms of epilepsy.
While earlier studies have demonstrated CRS blockade of voltage-gated sodium channels 
and action potential firing in hippocampal neurons,6,7 the mechanisms accounting for the 
beneficial effects of CRS remain unclear. Recently, CRS was found to decrease glutamate 
and increase glutamine brain levels in the rat lithium-pilocarpine model of TLE, but these 
effects were not consistently seen.8 Further, electrophysiological studies indicated that CRS 
reduces glutamatergic transmission by an action potential-dependent presynaptic 
mechanism.9 Given these observations, and the fact that neuronal hyperexcitability can arise 
from excessive intracellular calcium [Ca2+]i accumulation, we asked whether CRS might 
alter Ca2+ homeostasis in hippocampal neurons, and tested both direct and indirect effects of 
CRS on the four major cellular systems that regulate calcium, namely cell membrane-bound 
glutamate receptors, voltage-gated calcium channels, mitochondria and the endoplasmic 
reticulum (ER).
Methods
All experimental procedures were approved by the respective institutional animal care and 
use committees (IACUCs) where the relevant studies were conducted: Barrow Neurological 
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Institute at St. Joseph’s Hospital and Medical Center; the University of Kentucky 
(Lexington, KY, USA); and the University of Calgary (Calgary, Alberta, Canada).
Slice Electrophysiology
Male C3HeB/FeJ wild-type mice (4–7 weeks old) were anesthetized with isoflurane. 
Following decapitation, the brain was isolated and then submerged in ice-cold oxygenated 
physiological saline (124 mM NaCl, 1.8 mM MgSO4, 4 mM KCl, 1.25 mM NaH2PO4, 26 
mM NaHCO3, 2.4 mM CaCl2, and 10 mM D-glucose, [pH = 7.4]). Transverse hippocampal 
brain slices (300 μm) were cut using a vibratome and transferred to a perfusion chamber 
mounted on an Axioskop FS2 microscope (Carl Zeiss, Thornwood, NY, USA). Individual 
CA1 pyramidal neurons were visually identified under infrared-differential interference 
contrast (IR-DIC) optics. Tight-seal, whole-cell, patch-clamp recording was performed using 
borosilicate glass electrodes (4–7 MΩ) backfilled with an intracellular pipette solution 
composed of: 140 mM K-gluconate, 10 mM HEPES, 2 mM MgCl2, 1 mM CaCl2, 1 mM 
EGTA, and 2 mM K2ATP, pH = 7.25).
Cell Culture and Transient Transfection
To study T-type calcium channels,10 human Cav3.1 cDNA (Homo sapiens T calcium 
channel alpha 1G subunit variant 25, CACNA1G mRNA, complete cds, alternatively 
spliced) was expressed in tsA-201 human embryonic kidney (HEK) cells. HEK tsA-201 
cells were grown to 80~90% confluence at 37°C (5% CO2) in Dulbecco’s modified Eagle’s 
medium (Life Technologies, Grand Island, NY), supplemented with 10% (vol/vol) fetal 
bovine serum (HyClone, Thermo Scientific, Pittsburgh, PA), 200 U/ml penicillin, and 0.2 
mg/ml streptomycin (Life Technologies, Grand Island, NY). Cells were suspended with 
0.25% trypsin/ethylenediaminetetraacetic acid and plated onto glass coverslips in 10-cm 
culture dishes (Corning, Corning, NY) at 10% confluence 6 h before transfection. Calcium 
channel Cav3.1 (3 μg) and GFP marker (0.5 μg) DNAs were transfected into cells with 
calcium phosphate. Cells were transferred to 30°C 16–18 h later following transfection and 
stored for 2 days before recording.
Whole-Cell Electrophysiology
Cells on a glass coverslip were transferred into an external bath solution of 2 mM CaCl2, 1 
mM MgCl2, 155 mM TEA-Cl, 2.5 mM 4-AP, 10 mM HEPES, 10 mM glucose, pH 7.4. 
Borosilicate glass pipettes (Sutter Instrument Co., Novato, CA) (3–5 MΩ) were filled with 
internal solution containing 140 mM CsCl, 2.5 mM CaCl2, 1 mM MgCl2, 5 mM EGTA, 10 
mM HEPES, 2 mM Na-ATP and 0.3 mM Na-GTP, pH 7.3. Whole-cell patch clamp 
recordings were performed by using an EPC 10 amplifier (HEKA Elektronik, Bellmore, 
NY) linked to a personal computer equipped with Pulse (V8.65) software (HEKA 
Elektronik). After seal formation, the membrane beneath the pipette was ruptured and the 
pipette solution was allowed to dialyze into the cell for 2–5 min before recording. Voltage-
dependent currents were leak corrected with an online P/4 subtraction paradigm. Data were 
recorded at 10 kHz and filtered at 2.9 kHz. T-type calcium currents were elicited by 
depolarization from a holding potential of -110 mV to a test potential of −20 mV with an 
interpulse interval of 20 s. The duration of the test pulse was typically 40 ms. In current-
voltage relation studies for Cav3.1, the membrane potential was held at −110 mV and cells 
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were depolarized from −60 to +60 mV in 5 mV increments. In steady-state inactivation 
studies for Cav3.1, a 3 sec conditioning prepulse of various magnitudes (initial holding at 
−110 mV) was followed by a depolarizing pulse to −20 mV. Individual sweeps were 
separated by 12 s to permit recovery from inactivation between conditioning pulses. The 
current amplitude obtained from test pulse was normalized to that observed at the holding 
potential of −110 mV.
Data analysis was performed by using online analysis built in Pulse software (HEKA 
Elektronik), and all graphs and curve fittings were prepared by using GraphPad Prism 5 
(GraphPad Software, La Jolla, CA). Dose–response curves were fitted with the equation y = 
A2 + (A1 − A2)/(1 + ([C]/IC50)n), where A1 is initial current amplitude and A2 is the current 
amplitude at saturating drug concentrations, [C] is the drug concentration, and n is the Hill 
coefficient. Current–voltage relationships were fitted with the modified Boltzmann equation: 
I = [Gmax(Vm − Erev)]/[1 + exp((V0.5act − Vm)/κa)], where Vm is the test potential, V0.5act is 
the half activation potential, Erev is the reversal potential, Gmax is the maximum slope 
conductance, and κa reflects the slope of the activation curve. Steady-state inactivation 
curves were fitted using the Boltzmann equation: I = 1/(1 + exp((Vm − Vh)/κ)), where Vh is 
the half-inactivation potential and κ is the slope factor.
Calcium imaging and cell viability assay
Hippocampal slices were incubated with the calcium indicator dye Fura2-AM (10 μM; 
Invitrogen) for 1 hour. Each slice was transferred to a recording chamber fixed to an 
Axioskop FS2 IR-DIC microscope outfitted with the Zeiss Stallion 2 imaging system. 
Ratiometric fluorescence intensities in regions of interest were then recorded using a 340 
nm/380 nm excitation filter set controlled by a high-speed filter switching device. 
Photometric changes in fluorescence intensity (indicating alterations in free cytosolic 
[Ca2+]), were recorded before, during and after drug applications from CA3 pyramidal 
neurons every 10 sec.
To assess calcium release from the endoplasmic reticulum (ER), HEK293 cells were 
transfected with ryanodine receptor 2 (RyR2) cDNA using Ca2+ phosphate precipitation, and 
intracellular Ca2+ dynamics were measured as described previously.11 Briefly, transfected 
HEK293 cells were grown on glass coverslips for up to 24 hr, and then loaded with Fura2-
AM (5 μM) in KRH (Krebs-Ringer-HEPES) buffer (125 mM NaCl, 5 mM KCl, 1.2 mM 
KH2PO4, 6 mM glucose, 1.2 mM MgCl2 and 25 mM HEPES [pH = 7.4]) with 0.02% 
Pluronic F-127 and 0.1 mg/ml BSA for 20 min at room temperature (23 °C). Coverslips with 
dye-loaded HEK293 cells were then transferred to a perfusion chamber on an inverted 
microscope (Nikon TE2000-S). The chamber was constantly perfused with KRH buffer 
containing 2 mM Ca2+, and time-lapse images (0.5 frames/sec) were recorded on a PC and 
stored for offline analysis of fluorescence intensity using Compix Simple PCI 6 software 
(Compix Inc., Cranberry Township, PA, USA). Bath application of 2 mM Ca2+ evoked an 
oscillatory store Overload-Induced Calcium Release (SOICR) from the ER of HEK293 
cells, and the resulting changes in fluorescence intensity were used to quantify the amplitude 
and frequency of the SOICR.
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Neuroprotection Assays
Murine hippocampal HT-22 cells were cultured with Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 
mg/mL streptomycin. HT-22 cells were seeded in 96-well cell culture plates (5,000 cells per 
well) and grown overnight. Cells were then treated with either media alone or CRS followed 
by the addition of glutamate. After a 24-hr incubation, HT-22 cells were washed with PBS 
and loaded with 10 μM Fura2-AM for 1 hr at 37°C. Loaded cells were washed twice with 
DPBS, and the intracellular calcium level was measured with a plate reader by successive 
excitation of 340 nm and 380 nm. The emitted fluorescence was passed through a 510 nm 
filter. Quantification of the [Ca2+] was achieved by averaging the ratio of fluorescent signal 
acquired at 340 nm and 380 nm. To measure changes in cell survival against glutamate, 20 μl 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 2.5 mg/mL) was 
added to the wells and incubated for 3 hr. After incubation, the media was removed from the 
wells and 100 μL of dimethylsulfoxide (DMSO) was added to dissolve the formazan 
reagent. The absorbance was read using an Infinite m200 pro (TEKAN) reader at 565 nm. 
Cell viability was expressed as a percentage of the control group.
Mitochondrial isolation and mitochondrial membrane potential (ΔΨ) measurements
Our procedures were modified from previously described protocols.12 Isolated brains were 
homogenized in isolation buffer and subsequently centrifuged at 1,300 g for 3 min at 4°C. 
The isolated supernatant was centrifuged at 13,000 g for 10 min at 4 °C. The collected pellet 
was re-suspended in 1.5 ml of isolation buffer with 0.01% digitonin and then centrifuged at 
10,000 g for 10 min at 4°C. The pellet was re-suspended in 500 μl of isolation buffer. For 
Ficoll purification, the gradient was made by first loading the Ficoll 10% solution in the 
ultracentrifuge tube and then adding the Ficoll 7.5% solution. Loaded samples on top of the 
Ficoll gradient were centrifuged at 32,000 g for 30 min at 4°C. The collected pellet was re-
suspended in isolation buffer without EGTA and spun at 10,000 g for 10 min at 4°C. The 
pellet was again re-suspended in isolation buffer without EGTA, and then protein 
concentration was determined by a BCA protein assay kit.
ΔΨ was measured using the dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl 
carbocyanine iodide (MitoPTTM-JC1 kit; ImmunoChemistry Technologies). JC-1 emits 
green fluorescence at a low membrane potential (ΔΨ disruption), whereas polarized 
mitochondrial potentials reversibly form red fluorescent “J-aggregates” (ΔΨ stabilization). 
Briefly, aliquots of 250 μg of isolated mitochondrial protein were suspended in KCl 
respiration buffer (125 mM KCl, 2 mM MgCl, 2.5 mM KH2PO4, 20mM HEPES, and 0.1% 
BSA [pH 7.2]) mixed with tested drugs and 10 μM JC-1 to make a final volume of 200 μL 
and then incubated at 37°C for 30 min. Fluorescence intensity was measured with a TECAN 
SpectraFluor Microplate Reader (TECAN) under excitation and emission wavelengths of 
485 nm and 595 nm, respectively. Here, changes in red fluorescence intensities were 
indicative of ΔΨ and compared to the control optical density (OD) values.
Spectrofluorophotometer assays
Fractions enriched in mitochondria (200 μg protein/mL) were placed in 2 mL of KCl 
respiration buffer within a temperature-controlled cuvette at 37°C with 100 nM CaG5 N 
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(excitation 506 nm, emission 532 nm; to monitor extra-mitochondrial Ca2+) and 150 nM 
TMRE (excitation 550 nm, emission 575 nm; to monitor change in the mitochondrial 
membrane potential, ΔΨm) in a Shimadzu RF-5301PC spectrofluorophotometer (Shimadzu, 
Tokyo, Japan). Each time-scan began with a baseline reading followed by the addition of 5 
mmol/L pyruvate and 2.5 mmol/L malate at 1 min, 150 μmol/L ADP at 2 min, and 1 μmol/L 
oligomycin at 3 min. At 5 min, Ca2+ was added via an infusion syringe pump (80 nmol 
Ca2+/mg protein per minute) until the mitochondria were no longer able to buffer the added 
Ca2+. The chemical uncoupler, FCCP (1 μM; carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone), was added toward the end of the each run. The recorded 
traces, representative of at least three separate independent experiments, were quantified by 
calculating the average baseline CaG5 N fluorescence readings 1 min prior to the beginning 
of the Ca2+ infusion using the Shimadzu Hyper RF software (Shimadzu) and Microsoft 
Excel. The time-point at which the CaG5 N signal was 150% above the average baseline 
reading was considered the point at which mitochondria were overloaded and no longer 
capable of removing Ca2+ from the media, indicating onset of mitochondrial permeability 
transition (mPT).
Drugs and statistical analysis
All reagents used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
unless otherwise stated. Carisbamate (CRS) was obtained as a gift from Johnson & Johnson 
Pharmaceuticals and was dissolved in dimethylsulfoxide (DMSO) at various concentrations 
(but did not exceed 0.1%). Numerical data are expressed as the mean ± SEM. Student t-test 
or ANOVA was performed to determine differences among experimental groups, with 
significance set at p <0.05.
Results
Carisbamate inhibits kainic acid-evoked epileptiform activity in vitro
First, we assessed whether CRS diminishes kainic acid (KA)-evoked neuronal excitability in 
CA3 pyramidal neurons using acute hippocampal slices. Bath application of 10 μM KA 
induced long-lasting hyperexcitable changes superimposed on membrane depolarization (20 
out of 20 cells; Fig. 1A,D). Upon application of KA in cells pretreated with 100 μM CRS, 8 
out of 20 cells did not exhibit neuronal hyperexcitability. This effect was sustained up to 20 
min after washout (Fig. 1B,C,D). The attenuation of sustained action potential discharge was 
more pronounced with 300 μM CRS (22 out of 30 cells; Fig. 1C,D).
The inhibitory effects of CRS were also examined with either Mg2+-free physiological saline 
(which alleviates the Mg2+ block of N-methyl-D-aspartate [NMDA] receptors) or 300 μM 4-
aminopyridine (4-AP; a non-selective K+ channel blocker and Ca2+ channel activator). 
Under both of these experimental conditions, spontaneous rhythmic epileptiform discharges 
were seen, characterized by sustained over-riding action potentials (Fig. 1E). Consistent with 
anti-seizure effects previously seen in cortical slices,6 CRS (300 μM) blocked epileptiform 
discharges in both of these models (n = 7 cells/each study; Fig. 1E).
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CRS reduces KA-mediated intracellular Ca2+ influx
Given our initial results and prior literature showing increases in [Ca2+]i following glutamate 
receptor activation,13,14 we tested whether CRS could prevent elevations of [Ca2+]i after KA 
exposure using the intracellular Ca2+ indicator dye Fura2-AM. CRS did not alter the 
baseline fluorescence ratio (F340/380) when applied alone, whereas KA resulted in an 
immediate increase in [Ca2+]i in CA3 pyramidal neurons (n = 12; Fig. 2A). Consistent with 
our initial electrophysiological findings, pre-treatment with 300 μM CRS produced a 
substantial reduction in [Ca2+]i compared to cells treated solely with KA (n = 12; Fig. 2A).
We also reasoned that CRS would induce suppressive effects on zero-Mg2+-evoked 
epileptiform discharges. To confirm this, we measured glutamate-mediated [Ca2+]i 
accumulation in murine hippocampal HT-22 cells with and without CRS using Fura2-AM. 
In these cells, CRS alone (10 and 100 μM) had no influence on [Ca2+]i levels, but both 5 
mM and 10 mM glutamate dose-dependently increased the level of [Ca2+]i compared to 
HT-22 cells exposed only to media (Fig. 2B). When 5 mM glutamate was co-applied with 
either 10 μM or 100 μM CRS, the [Ca2+]i level declined significantly by 19% (117 ± 5, n = 
10) and 33% (104 ± 5.7, n = 10), respectively, compared to cells treated with 5 mM 
glutamate alone (136 ± 3.2, n = 10). No differences were seen with media alone, compared 
to 100 μM CRS plus 5 mM glutamate. At 10 mM glutamate (along with either 10 μM or 100 
μM CRS), [Ca2+]i levels were significantly reduced by 40% (131 ± 7.5, n = 10) and 54% 
(117 ± 6, n = 10), respectively, compared to cells treated with 10 mM glutamate alone (171 
± 6, n = 10) (Fig. 2B). These data further support the notion that CRS contributes to an anti-
seizure action by decreasing pathological [Ca2+]i influx.
CRS prevents glutamate-induced neuronal injury
Next, we sought to determine whether the reduction in [Ca2+]I by CRS could be correlated 
with morphological neuroprotection. Using a live-cell imaging system, HT-22 cells exposed 
to 500 μM glutamate alone for 24 hr resulted in a 40% decrease in cell viability (Fig. 3A). 
However, cells treated concomitantly for 1 hr with 100 μM CRS and 500 μM glutamate 
appeared healthy. 100 μM CRS alone had no influence on cell survival (Fig. 3B).
CRS does not affect ER- or mitochondria-mediated changes in [Ca2+]i
While neuronal hyperexcitability involves increased accumulation of [Ca2+]i, prolonged 
depolarization also triggers the release of Ca2+ from the ER through inositol 1,4,5-
trisphosphate (IP3) and ryanodine receptors.15 Further, aberrant [Ca2+]i overloading can 
arise from mitochondrial dysfunction, such as the disruption of mitochondrial membrane 
potential (Δψ) and mitochondrial permeability transition (mPT) opening.16,17 Irrespective of 
the actual causes of pathological rises in [Ca2+]i, the net effect is activation of cell death 
cascade.14
Given the important role of the ER and mitochondria in regulating intracellular calcium 
levels, we asked whether CRS might affect either one or both of these organelles and 
processes regulating intracellular calcium homeostasis. It has been shown that store Ca2+ 
overload can trigger spontaneous Ca2+ oscillations (store overload-induced Ca2+ release, or 
SOICR) via the ryanodine receptor.18 We next determined the impact of CRS on SOICR. 
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There were no differences amongst groups treated with various CRS doses compared to 
controls, with respect to either the amplitude or frequency (n = 3–5 for each dose; Fig. 4A). 
However, the SOICR amplitude in the 1 mM CRS-treated group was significantly lower 
compared to that seen when lower doses of CRS and DMSO (control) were used (Fig. 4B, p 
< 0.05); however, SOICR frequency was not changed with 1 mM CRS administration.
Next, we explored a potential modulatory effect of CRS on the mitochondrial membrane 
potential (Δψ) or Ca2+-induced mPT. Acutely isolated hippocampal mitochondria were 
prepared, and exposed to CRS. We monitored the change in Δψ from JC1-loaded isolated 
mitochondria treated with either 10 μM KA or 300 μM CRS for 30 min. Neither KA nor 
CRS separately altered Δψ. In contrast, application of 100 nM rotenone (Rot), a toxic 
compound that acts by inhibiting Complex I of the electron transport chain, triggered a 
significant decrease in ΔΨ (Fig. 5A, p < 0.01) as previously reported,19 but 300 μM CRS 
had no effect on the Rot-evoked ΔΨ depolarization (Fig 5A). Given that a potential 
pathological correlation exists between calcium overloading and mPT activation, we then 
asked whether CRS can regulate Ca2+-induced mPT. We found that CRS alone did not affect 
the threshold for Ca2+-induced mPT opening (Fig. 5B,C).
CRS inhibits T-type Ca2+ channels
In the genetic absence epilepsy rat of Strasbourg (GAERS) model, CRS was found to 
strongly suppress spike-wave-discharges.20 While there are many drugs that exhibit similar 
effects, the prototypic agent and first-line therapy for absence epilepsy, ethosuximide, is 
known to block low-threshold, T-type Ca2+ channels which play a pivotal role in the genesis 
of absence seizures in the thalamocortical network.21–24 To investigate the possibility that 
CRS interacts with T-type Ca2+ channels, we performed whole-cell recordings in tsA-201 
HEK cells expressing Cav3.1 channels. Fast-inactivating T-type currents, generated by 
recombinant Cav3.1 channels, were generated in response to depolarizing pulses (Fig. 6). 
With infusion of 100 μM CRS, a reduction in the T-type current was seen, with a peak effect 
when depolarized from −110 mV to −30 mV (Fig. 6A,B). The current-voltage relationship 
of T-type Ca2+ channel in response to CRS under different voltage steps revealed a 
significant decrease in whole-cell current amplitude across a wide range of voltages (Fig. 
6C). There was a significant shift in the half-inactivation potential upon application of 300 
μM CRS (Fig. 6D), indicating that this compound is able to stabilize the inactivated state of 
the channel. Importantly, this shift resulted in further inhibition of whole-cell current 
amplitudes at more depolarized membrane potentials. In additional experiments, we found 
no modulatory effects of 100 μM and 300 μM CRS on HEK cells transfected with Cav3.2 
channels (n = 3; data not shown). Collectively, these results support our notion that the T-
type Ca2+ channel – specifically, the Cav3.1 isoform – is a target of CRS action, and may 
play an important role in regulating not only intracellular Ca2+ but importantly, the anti-
seizure and neuroprotective effects seen with this novel anti-seizure medication.
Discussion
In the present study, we show that CRS can inhibit KA-induced neuronal hyperexcitability, 
elevations in [Ca2+]i, and subsequent hippocampal cell death in a dose-dependent manner. 
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While a direct mechanistic link to ryanodine receptors or to mitochondrial function could 
not be established, we nevertheless found that a clinically relevant concentration, CRS (300 
μM) was able to significantly attenuate T-type Ca2+ currents in HEK cells transfected with 
recombinant Cav3.1 channels. Thus, after evaluating several major sources of calcium influx 
into the cell, we conclude from our data that the anti-seizure and morphological 
neuroprotective effects of CRS are likely due in part to blockade of T-type Ca2+ channels.
It is well known that KA-induced epileptogenesis is associated with activation of voltage-
dependent calcium channels25,26 which contributes to neuronal hyperexcitability and 
subsequent cell death.13,27 Our current findings are in keeping with the extensive prior 
literature, and more specifically with in vivo and in vitro experiments wherein CRS was 
demonstrated to reduce seizure activity induced by KA.28 Blockade of T-type calcium 
current constitutes a possible mechanism of action of CRS that augments inhibition of 
voltage-gated Na+ channels, as evidenced by earlier studies revealing CRS’s ability to 
decrease membrane input resistance and diminish action potential firing.6,7
With respect to neuronal injury, prolonged elevation in [Ca2+]i following the activation of 
glutamate receptors is widely accepted as a key factor in the processes of both neuronal 
injury and epileptogenesis.29 In this regard, our findings in the in vitro zero-Mg2+ model 
(Fig. 1E) are also consistent with the linkage between “seizure-like” epileptiform discharges 
and glutamate receptor-mediated calcium influx.30 Further, we show that CRS was able to 
exert effects against glutamate, similar to what was seen with KA exposure, specifically a 
normalization of [Ca2+]i levels (Fig. 2). This is consistent with the previously demonstrated 
inhibition of “seizure-like” rhythmic discharges in hippocampal slices bathed in zero-Mg2+ 
aCSF.6,31
Excessive glutamate (specifically, NMDA) receptor activation, while impairing [Ca2+]i 
homeostasis, can also facilitate release of Ca2+ through ryanodine receptors (RyRs) from the 
ER.32 While there are compelling data that CRS can suppress glutamate-mediated synaptic 
transmission in the granule cells of the dentate gyrus,9 we could not confirm a direct effect 
of CRS on RyRs in the ER. However, it is likely that the inhibitory action of CRS on 
glutamate neurotransmission and blockade of T-type Ca2+ channels can secondarily reduce 
the calcium burden on the ER.
The other major organelle to consider when studying intracellular calcium homeostasis is the 
mitochondrion. There is abundant evidence that mitochondria can act as a Ca2+ buffer under 
conditions of NMDA-evoked increases in [Ca2+]i, thereby helping to prevent neuronal injury 
or death.33 However, when cellular homeostatic and compensatory systems fail to contain 
pathological rises in [Ca2+]i, or when excessive mitochondrial Ca2+ accumulation occurs, 
cell death pathways are triggered via depolarization of Δψ and opening of the mitochondrial 
permeability transition pore.16,17 In the present study, activation of kainate receptors 
elevated [Ca2+]i in CA3 pyramidal neurons, but KA alone was unable to alter Δψ in isolated 
mitochondria, suggesting that the pharmacological actions of KA are likely upstream of the 
mitochondrion. Similarly, neither Δψ nor Ca2+-induced mPT opening was affected after 
exposure to CRS. Despite the lack of direct interaction of CRS on mitochondria, we cannot 
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exclude the possibility that the upstream modulation of [Ca2+]i influx by CRS reduces 
overall mitochondrial Ca2+ accumulation.
It is well established that T-type Ca2+ channels are critically involved in absence 
seizures 33–37 and that specific blockers of Cav3.1 exert anti-seizure activity in both humans 
and animal models.37,38 Consistent with these data, we observed that Cav3.1 (but not 
Cav3.2) Ca2+ currents were significantly attenuated by clinically relevant concentrations of 
CRS. We did not, however, evaluate the effects of CRS on high voltage-activated (HVA) 
calcium channels, as an earlier study indicated that selective HVA blockers were unable to 
reverse the inhibitory effect of CRS on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA)-mediated excitatory post-synaptic currents.9 Curiously though, unlike the 
prototypic T-type calcium channel blocker ethosuximide, CRS appears to have greater 
broad-spectrum activity in multiple animal models of seizures and epilepsy,39 suggesting 
other yet undefined mechanisms of action.8,9 To this point, CRS has been shown to inhibit 
glutamatergic neurotransmission in the dentate gyrus through an action potential-dependent 
mechanism, but not through pre-synaptic calcium channels.9
In summary, we provide evidence that the anti-seizure and neuroprotective effects of CRS 
may be explained partly on the basis of its ability to block T-type calcium channels in 
neurons, and also by preventing excessive intracellular calcium accumulation such as would 
occur through glutamate receptor activation. CRS also inhibits voltage-gated sodium 
channels, and there is recent evidence that this novel monocarbamate compound can 
modulate the activation of a GABA-mediated chloride conductance.6,7 Thus, with growing 
evidence that CRS may afford functional and neuroprotective – as well as disease-modifying 
– effects beyond epilepsy, the greater elucidation of basic mechanisms underlying these 
actions may lead to the development of analog compounds having similar profiles.
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Bullet Points
• Carisbamate (CRS) reversed kainic acid-induced elevations in intracellular 
calcium in CA3 pyramidal neurons
• CRS blocked epileptiform activity in hippocampal slices exposed to zero-
Mg2+ or 4-AP
• CRS did not affect mitochondrial respiratory chain activity or Ca2+ release 
from the endoplasmic reticulum
• CRS decreased Ca2+ flux in HEK tsA-201 cells transfected with Cav3.1 
voltage-dependent T-type Ca2+ channels
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Figure 1. Effects of carisbamate (CRS) on epileptiform activity provoked under different 
conditions in vitro
(A) Bath application of 10 μM KA led to membrane depolarization and hyperexcitability of 
CA3 pyramidal neurons in acute hippocampal slices. (B, C) Pre-treatment with 100 μM CRS 
suppressed KA-induced neuronal hyperexcitability in 8 out of 20 cells, with the remainder 
being unaffected. Increasing CRS to 300 μM CRS led to 22 out of 30 cells being protected. 
(D) Summary of neuronal excitability changes following KA exposure alone, or with either 
100 μM CRS or 300 μM CRS. Each vertical bar represents the percentage (%) of cells 
exhibiting neuronal hyperexcitability during combined KA and CRS application. (E) 
Representative traces depicting spontaneous “seizure-like” epileptiform activity beginning 
30 min after continuous infusion of zero-Mg2+ physiological saline (upper panel) or 
perfusate containing 300 μM 4-aminopyridine (4-AP). Under both conditions, 300 μM CRS 
decreased epileptiform activity. RMP indicates resting membrane potential.
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Figure 2. Effect of carisbamate (CRS) on calcium influx induced by either kainic acid (KA) or 
glutamate
(A) Following exposure to KA, the fluorescence ratio (at 340 and 380 nm excitation 
wavelengths; F340/380) increased dramatically in CA3 pyramidal neurons. While CRS 
alone did not alter the fluorescence signal, cells pre-treated with CRS showed a prominent 
reduction in calcium fluorescence intensity in the face of KA exposure. Photomicrograph 
series (I–V) at various time-points during KA and CRS challenge are shown, reflecting 
changes in [Ca2+]i in pyramidal neurons as labeled with Fura2-AM; the white rectangles at 
time-point I depict Fura-2AM signals. (B) Changes in [Ca2+]i load in HT-22 cells exposed to 
glutamate with or without CRS. Increases in [Ca2+]i were seen following both 5 mM and 10 
mM glutamate; these changes were attenuated in a dose-dependent manner by 10 μM and 
100 μM of CRS. (*, compared to control cells vs. glutamate-treated cells; # compared to 5 
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mM glutamate-treated cells vs. 5 mM glutamate plus CRS-treated cells; † compared to 10 
mM glutamate plus CRS-treated cells). CRS alone did not affect calcium accumulation. 
Values represent group means ± S.E.M. One-way ANOVA followed by Tukey test; **, p < 
0.01; ***, p < 0.001; #, p < 0.05; ##, p < 0.01; ††, p < 0.01; †††, p < 0.001.
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Figure 3. Carisbamate (CRS) is neuroprotective against glutamate-induced cell death
(A) Representative images of HT-22 cells 12 hr after administration with media alone 
(control), 5 mM glutamate (Glu), and Glu plus 100 μM CRS. (B) Summary data of cell 
viability using the MTT assay for various treatment groups. Glu alone produced over 40% 
cell death and this effect was dose-dependently suppressed by CRS. Values represent group 
means ± S.E.M. One-way ANOVA followed by Tukey test; *, p < 0.05.
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Figure 4. Effect of carisbamate (CRS) on Store Overload-Induced Ca2+ Release (SOICR) in 
endoplasmic reticulum (ER)
Summary of single-cell fluorescence intensity measurements of SOICR with either DMSO 
(vehicle) alone or at various concentrations of CRS. (A) CRS did not significantly alter the 
frequency of store overload-evoked Ca2+ oscillations. (B) Despite a slight (but non-
significant) reduction in the amplitude of store overload-evoked Ca2+ oscillations over the 
CRS dose range of 30–300 μM, no significant differences were seen. However, at 1 mM 
CRS, the amplitude of the store overload-evoked oscillations was significantly suppressed 
by CRS (student t-test; *, p < 0.05).
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Figure 5. Effects of carisbamate (CRS) in acutely isolated hippocampal mitochondria
(A) No differences in the mitochondrial membrane potential (Δψ) were seen with either 300 
μM CRS or 10 μM KA. After the addition of 100 nM rotenone (Rot), Δψ dissipated 
substantially but this action was not prevented by CRS. One way ANOVA followed by 
Tukey test; **, p < 0.01. (B, C) Representative traces and summary data depicting Ca2+-
induced mPT opening with and without CRS treatment. CRS (300 μM) did not affect mPT. 
Values represent mean ± S.E.M. Paired t-test was conducted between control vs CRS-treated 
groups.
Kim et al. Page 19
Epilepsia. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Effect of carisbamate (CRS) on cells transfected with Cav3.1 (T-type calcium) channels
(A) Representative traces showing Ca2+ currents recorded before and after bath application 
of 300 μM CRS. There is a significant decrease in the peak amplitude of the current in 
response to a depolarizing step up from −110 mV to −30 mV. The remaining Cav3.1 current 
was 83.2 ± 1.9% (p = 0.02, paired t-test, n = 6) and 71.2 ± 4.2% (p = 0.00003, paired t-test, 
n = 6) after application of CRS at 100 μM and 300 μM, respectively. (B) Bar graph 
summarizing the peak Ca2+ current amplitudes elicited with and without CRS (100 and 300 
μM) treatment. (C) Current-voltage relationship for CRS block of Cav3.1. The half-
activation potential from the fitted curves were −50.1 ± 0.4 mV and −51.2 ± 0.6 mV for 
before and after the application of CRS (300 μM, n = 6), p = 0.51 (paired t-test). (D) The 
steady-state inactivation curve for CRS block of Cav3.1. The half inactivation potential from 
the fitted curves were −62.6 ± 0.8 and −68.9 ± 1.0 for before and after the application of 
CRS (300 μM, n = 6), p = 0.0007 (paired t-test).
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